Delcath Systems Inc (fra:DV3R) Share Price

Company Profile

Business description
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Contact
566 Queensbury Avenue
QueensburyNY12804
USA
T: +1 212 489-2100
E: [email protected]
https://www.delcath.com
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
76

Recommended

These undervalued stocks of high-quality companies could be attractive investments today.

Margaret Giles | 17 March 2025

Ben Graham was the king of flipping deep value stocks. The best investment of his life came from something very different.

Joseph Taylor | 17 March 2025

These shares have surged in price in the last year but are significantly overvalued according to our analysts.

Morningstar | 16 March 2025

Index	Last price	Change	% Change
All Ordinaries	8,082.10	68.80	0.86%
CAC 40	8,073.98	45.70	0.57%
DAX 40	23,154.57	167.75	0.73%
Dow JONES (US)	41,841.63	353.44	0.85%
FTSE 100	8,680.29	47.96	0.56%
HKSE	24,145.57	185.59	0.77%
NASDAQ	17,808.66	54.58	0.31%
Nikkei 225	37,396.52	343.42	0.93%
NZX 50 Index	12,154.23	11.91	-0.10%
S&P 500	5,675.12	36.18	0.64%
S&P/ASX 200	7,854.10	64.40	0.83%
SSE Composite Index	3,426.13	6.57	0.19%